For Lab R&D Uses Only

Purity:               >98% (HPLC)

Product Description:

Novel potent and selective CDK2 Inhibitor for treatment of solid tumors including small cell lung cancer, metastatic breast cancer, HR positive metastatic breast cancer, HER2 negative and positive metastatic breast cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer (PPC), triple negative breast cancer and non-small cell lung cancer, inducing cell cycle arrest and apoptosis, suppressing tumor cell proliferation

Reference:

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.3010

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239507/

Analytical data

Price & Availability